The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

3-Year Outcomes of Mitral Valve-in-Valve Therapy Using Balloon-Expandable Transcatheter Valves in the United States

Eleid MF, Krishnaswamy A, Kapadia S, Yadav P, Rajagopal V, Makkar R, Stinis C, Chetcuti S, Morse A, Frisoli T, Frangieh AH, Abbas AE, Whisenant[...]

The Association of Arsenic Exposure and Metabolism Biomarkers with Subclinical Measures of Liver Disease: a cross-sectional investigation in the Multi-Ethnic Study of Atherosclerosis

Wu HC, Glabonjat RA, Schilling K, Anderson WA, Gao S, Relloso AD, LoIacono N, Slowly M, Nigra AE, Sanchez T, Sobel MH, Galvez-Fernandez M, Budoff[...]

Clinical and socioeconomic factors associated with recurrent atrial fibrillation after catheter ablation or antiarrhythmic drug therapy

An J, Bansal N, Zheng C, Lee MS, Wei R, Harrison TN, Fan D, Garcia E, Lidgard B, Zelnick LR, Singer DE, Go AS. Clinical[...]